UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C.  20549
_____________

FORM 8-K
_____________

CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934


Date of report (Date of earliest event reported):  September 16, 2009


Keryx Biopharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)


Delaware
(State or Other Jurisdiction
of Incorporation)
000-30929
(Commission File Number)
 
13-4087132
(IRS Employer Identification No.)


750 Lexington Avenue
New York, New York 10022
(Address of Principal Executive Offices)

(212) 531-5965
(Registrant's telephone number, including area code)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

£  
Written communications pursuant to Rule 425 under the Securities Act.
£  
Soliciting material pursuant to Rule 14a-12 under the Exchange Act.
£  
Pre-commencement communications pursuant to Rule 14d-2b under the Exchange Act.
£  
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

 
Item 8.01 Other Events.
 
 
On September 16, 2009, Keryx issued a press release announcing that Keryx received notice from the U.S. Food and Drug Administration on orphan-drug status for Perifosine in Multiple Myeloma. A copy of the press release is being furnished as Exhibit 99.1 to this report.
 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 
Keryx Biopharmaceuticals, Inc.
(Registrant)
  
       
       
Date:  September 16, 2009
By:
/s/ James F. Oliviero
  
   
James F. Oliviero
  
   
Chief Financial Officer
  
 
 
INDEX TO EXHIBITS

Exhibit Number
Description
  

99.1 
Press Release dated September 16, 2009